Results 221 to 230 of about 384,231 (258)

Using Antibody Arrays for Biomarker Discovery

2020
Biomarkers for diseases are important for the development of clinical diagnostic tests and can provide early intervention for cancer or cardiovascular patients. Over the past decade, antibody array technology has achieved significant technological improvement in the quantitative measurement of more than a thousand proteins simultaneously and has been ...
Shuhong, Luo, Yunbiao, Ling, Li-Pai, Chen, Ruo-Pan, Huang   +3 more
openaire   +2 more sources

Ligand-Directed GPCR Antibody Discovery

2022
Developing affinity reagents recognizing and modulating G-protein coupled receptors (GPCR) function by traditional animal immunization or in vitro screening methods is challenging. Some anti-GPCR antibodies exist on the market, but the success rate of development is still poor compared with antibodies targeting soluble or peripherally anchored proteins.
Qi, Zhao, Amanda, Chapman, Yan, Huang, Mary, Ferguson, Shannon, McBride, Meghan, Kelly, Michael, Weiner, Xiaofeng, Li   +7 more
openaire   +2 more sources

Phenotypic screening: the future of antibody discovery

Drug Discovery Today, 2016
Most antibody therapeutics have been isolated from high throughput target-based screening. However, as the number of validated targets diminishes and the target space becomes increasingly competitive, alternative strategies, such as phenotypic screening, are gaining momentum.
Andrea L, Gonzalez-Munoz, Ralph R, Minter, Steven J, Rust   +2 more
openaire   +2 more sources

Discovery and development of bispecific antibodies

Protein Expression and Purification
Bispecific antibodies (BsAbs) represent a significant breakthrough in antibody-based therapeutics, offering the unique capability to engage two distinct targets simultaneously. BsAbs are expected to exert therapeutic effects that are unattainable with conventional antibody drugs. Specifically, they are being developed for use in intercellular bridging,
Tetsuya Wakabayashi, Taichi Kuramochi
openaire   +2 more sources

Deep Sequencing Approaches to Antibody Discovery

Current Drug Discovery Technologies, 2014
Antibodies have become one of the dominant therapeutic platforms due to their safety, specificity, and efficacy. Owing to their massive potential diversity intrinsic to their structure, the number of possible different molecules that could be generated and analyzed from natural or synthetic systems is almost limitless.
Michael F, Naso, Jin, Lu, Tadas, Panavas
openaire   +2 more sources

Antibody Discovery: Sourcing of Monoclonal Antibody Variable Domains

Current Drug Discovery Technologies, 2014
Historically, antibody variable domains for therapeutic antibodies have been sourced primarily from the mouse IgG repertoire, and typically either chimerized or humanized. More recently, human antibodies from transgenic mice producing human IgG, phage display libraries, and directly from human B lymphocytes have been used more broadly as sources of ...
openaire   +2 more sources

The role of therapeutic antibodies in drug discovery

Biochemical Society Transactions, 2003
The last 5 years have seen a major upturn in the fortune of therapeutic monoclonal antibodies (mAbs), with nine mAbs approved for clinical use during this period and more than 70 now in clinical trials beyond phase II. Sales are expected to reach $4 billion per annum worldwide in 2002 and $15 billion by 2010.
L H, Stockwin, S, Holmes
openaire   +2 more sources

Therapeutic antibodies: Discovery, design and deployment

Molecular Immunology, 2015
Therapeutic antibodies have come of age with major progress being made in cancer, autoimmunity and chronic inflammation, as well as a wide range of other human diseases. Antibody engineering is further driving development of novel antibody formats and genetically modified cell-based therapies that harness the power of the immune system to progress ...
Ramsland, Paul, Hutchinson, A., Carter, P.   +2 more
openaire   +3 more sources

Antiphospholipid antibodies: discovery, definitions, detection and disease

Progress in Lipid Research, 2003
Antiphospholipid antibodies (aPL) are immunoglobulins of IgG, IgM and IgA isotypes that target phospholipid (PL) and/or PL-binding plasma proteins. Detection of aPL in the laboratory is done currently by both immunoassays and functional coagulation tests.
John A, McIntyre, Dawn R, Wagenknecht, W Page, Faulk   +2 more
openaire   +2 more sources

Antibody Microarrays as Tools for Biomarker Discovery

2011
The cancer biomarkers field is being enriched by molecular profiling obtained by high-throughput approaches. Targeted antibody arrays are strongly contributing to the identification of protein cancer -biomarker candidates and functional proteomic analyses.
openaire   +2 more sources